432 related articles for article (PubMed ID: 18156607)
1. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis.
Karakousis PC; Williams EP; Bishai WR
J Antimicrob Chemother; 2008 Feb; 61(2):323-31. PubMed ID: 18156607
[TBL] [Abstract][Full Text] [Related]
2. A human-like TB in genetically susceptible mice followed by the true dormancy in a Cornell-like model.
Radaeva TV; Kondratieva EV; Sosunov VV; Majorov KB; Apt A
Tuberculosis (Edinb); 2008 Nov; 88(6):576-85. PubMed ID: 18667358
[TBL] [Abstract][Full Text] [Related]
3. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
[TBL] [Abstract][Full Text] [Related]
4. Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using Genechips.
Fu LM; Shinnick TM
Tuberculosis (Edinb); 2007 Jan; 87(1):63-70. PubMed ID: 16890025
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis.
Saliu OY; Crismale C; Schwander SK; Wallis RS
J Antimicrob Chemother; 2007 Nov; 60(5):994-8. PubMed ID: 17761500
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
[TBL] [Abstract][Full Text] [Related]
7. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
[TBL] [Abstract][Full Text] [Related]
8. A mathematical representation of the development of Mycobacterium tuberculosis active, latent and dormant stages.
Magombedze G; Mulder N
J Theor Biol; 2012 Jan; 292():44-59. PubMed ID: 21968442
[TBL] [Abstract][Full Text] [Related]
9. [Quantitative analysis of sigma genes expression in Mycobacterium tuberculosis cultures exposed to rifampicin and isoniazid].
Pendzich J; Maksymowicz-Mazur W; Mazurek U; Dworniczak S; Oklek K; Kozielski J; Wilczok T
Wiad Lek; 2004; 57(5-6):233-40. PubMed ID: 15518067
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy.
Voskuil MI; Visconti KC; Schoolnik GK
Tuberculosis (Edinb); 2004; 84(3-4):218-27. PubMed ID: 15207491
[TBL] [Abstract][Full Text] [Related]
11. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
[TBL] [Abstract][Full Text] [Related]
12. Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex.
Shenai S; Rodrigues C; Mehta A
Int J Infect Dis; 2009 Jan; 13(1):46-58. PubMed ID: 18565777
[TBL] [Abstract][Full Text] [Related]
13. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa.
Evans J; Stead MC; Nicol MP; Segal H
J Antimicrob Chemother; 2009 Jan; 63(1):11-6. PubMed ID: 18940875
[TBL] [Abstract][Full Text] [Related]
14. PPE_MPTR genes are differentially expressed by Mycobacterium tuberculosis in vivo.
Soldini S; Palucci I; Zumbo A; Sali M; Ria F; Manganelli R; Fadda G; Delogu G
Tuberculosis (Edinb); 2011 Nov; 91(6):563-8. PubMed ID: 21890414
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
[TBL] [Abstract][Full Text] [Related]
16. [Effects of antibacterial preparations on growth of Mycobacterium tuberculosis in a model of primary tuberculous infection in tissue culture].
Kunichan AD; Sokolova GB; Shapatava MN
Probl Tuberk; 1994; (5):40-3. PubMed ID: 7870726
[TBL] [Abstract][Full Text] [Related]
17. Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Rodrigues-Junior VS; Dos Santos Junior A; Dos Santos AJ; Schneider CZ; Calixto JB; Sousa EH; de França Lopes LG; Souto AA; Basso LA; Santos DS; Campos MM
Int J Antimicrob Agents; 2012 Aug; 40(2):182-5. PubMed ID: 22748570
[TBL] [Abstract][Full Text] [Related]
18. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
Taneja NK; Tyagi JS
J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
[TBL] [Abstract][Full Text] [Related]
19. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
Sriram D; Yogeeswari P; Yelamanchili Priya D
Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
[TBL] [Abstract][Full Text] [Related]
20. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice.
Karakousis PC; Yoshimatsu T; Lamichhane G; Woolwine SC; Nuermberger EL; Grosset J; Bishai WR
J Exp Med; 2004 Sep; 200(5):647-57. PubMed ID: 15353557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
